« Previous
Next »
Titles
- Drug development: FDA's priority review voucher programs : report to Congressional committees1
- Drug development: Pathway for approving antibacterial and antifungal drugs for patients with limited treatment options is infrequently used : report to congressional committees1
- Drug misuse: agencies have not fully identified how grants that can support drug prevention education programs contribute to national goals : report to Congress1
- Drug misuse: sustained national efforts are necessary for prevention, response, and recovery : report to the Congress1
- Drug price increases that exceed inflation are costing Medicare Part D billions1
- Drug price moderation in Germany: lessons for U.S. reform efforts1
- Drug safety: COVID-19 complicates already challenged FDA foreign inspection program : testimony before the Committee on Finance, U.S. Senate1
- Dual Medicare-Medicaid enrollment and integrated plan identification: T-MSIS analytic files data quality1
- Duty hour reform and the outcomes of patients treated by new surgeons: evaluating a new paradigm in surgical training1